Zymeworks Inc. (ZYME) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Zymeworks Inc. (ZYME)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

13.56

-0.40 (-2.87%)

At close: Jan 14, 2025, 3:59 PM

13.62

0.44%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	13.3
Market Cap	933.98M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.49
PE Ratio (ttm)	-9.1
Forward PE	n/a
Analyst	Hold

Ask	14.2
Volume	248,346
Avg. Volume (20D)	526,606
Open	14.14
Previous Close	13.96
Day's Range	13.34 - 14.14
52-Week Range	7.97 - 17.70
Beta	undefined

About ZYME

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 28, 2017

Employees 294

Stock Exchange NYSE

Ticker Symbol ZYME

Website https://www.zymeworks.com

Analyst Forecast

According to 6 analyst ratings, the average rating for ZYME stock is "Hold." The 12-month stock price forecast is $18, which is an increase of 32.74% from the latest price.

Buy 66.67%

Hold 33.33%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Zymeworks Inc. is scheduled to release its earnings on Mar 5, 2025, during market hours.
Analysts project revenue of $62.47M, reflecting a 269.08% YoY growth and earnings per share of 0.19, making a -218.75% decrease YoY.

Why Price Moved

4 weeks ago · Source

+9.46%

Zymeworks shares are trading higher after JP Morga... Unlock content with Pro Subscription

News

1 week ago · zacks.com

Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 41.36%: Here's is How to Trade

The mean of analysts' price targets for Zymeworks (ZYME) points to a 41.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys...

3 weeks ago · seekingalpha.com

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

The Zymeworks story over the last two years was one of transformation and execution. Ziihera (zanidatamab) was approved in November for the treatment of second line biliary tract cancer and Zymeworks ...

4 weeks ago · https://thefly.com

Zymeworks upgraded to Overweight from Neutral at JPMorgan

JPMorgan upgraded Zymeworks to Overweight from Neutral with an $18 price target.

2 months ago · seekingalpha.com

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab

The PDUFA date for potential approval of Zanidatamab for the treatment of patients with 2nd-line biliary tract cancer set for November 29th of 2024. Progression-free survival data from the phase 3 HER...

2 months ago · seekingalpha.com

Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript

Zymeworks Inc. (NASDAQ:ZYME ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice Presiden...

2 months ago · zacks.com

Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.41 per share a year ago.